Multi-outcome AI-ECG risk-estimation platform that turns a single 12-lead ECG into a patient-specific survival curve, using a residual convolutional neural network trained with a discrete-time survival loss to predict not just risk but time-to-event. Beyond all-cause and cardiovascular mortality, separately fine-tuned heads predict future ventricular arrhythmia, complete heart block, atrial fibrillation, atherosclerotic cardiovascular disease, heart failure, and (in follow-up work) hypertension -- all from a single resting ECG, including in ECGs a cardiologist would read as normal. Derived on 1.16 million ECGs from 189,539 Beth Israel Deaconess Medical Center patients and externally validated across transnational cohorts in the USA, Brazil (CODE), and the UK (UK Biobank). A variational autoencoder and genome/phenome-wide association analyses were used to show the model's predictions track biologically plausible features (QRS morphology, LV structure/function, and loci linked to cardiac structure, QT interval, and biological aging). NHS trials of AIRE were planned for late 2025. No public code or model weights have been released.

Supervised EfficientNetV2-based 12-lead ECG model trained on over 1 million ECGs from the Montreal Heart Institute to predict 77 cardiac conditions derived from American Heart Association recommendations, plus fine-tuned digital-biomarker heads for reduced LVEF, 5-year atrial-fibrillation risk, and long-QT-syndrome (LQTS) detection/genotyping. Validated on 881,403 ECGs across 11 geographically diverse cohorts (4 public, 7 private health systems), achieving AUROCs above 0.98 for the 77-condition interpretation task while being 60x smaller and 29x faster at inference than its self-supervised DeepECG-SSL counterpart, with up to 9.7x lower CO2 emissions on equivalent tasks.

Self-supervised EfficientNetV2-based 12-lead ECG foundation model pretrained via contrastive learning and masked-lead modeling on 1.9 million ECGs (Montreal Heart Institute plus CODE-15% and MIMIC-IV), then fine-tuned for the same 77-condition ECG interpretation task and digital-biomarker extraction as DeepECG-SL. Outperforms the supervised counterpart on label-scarce digital-biomarker tasks, with the largest gains on LQTS genotype classification (AUROC 0.931 vs. 0.850, n=127 ECGs) and 5-year atrial-fibrillation risk (AUROC 0.742 vs. 0.734, n=132,050 ECGs), and outperforms ECG-FM and ECGFounder on shared external diagnostic classes.